STAT News, February 2, 2024: NCHR’s Diana Zuckerman’s commentary in STAT News explains why Medicare should not pay for every medical product that FDA approves, since some are more likely to harm rather than help Medicare patients. She points out that FDA does not require diversity in clinical trials and rarely includes enough older and less healthy patients that tend to rely on Medicare.
Read More »Author: Caroline Bradford
NCHR’s Comment on EPA’s Proposed Lead and Copper Rule Improvements (LCRI)
February 2024: In its public comment, NCHR supported EPA’s proposed lead and copper rule improvements (LCRI) and suggested strengthening safeguards such as lowering the action lead level to 5 ppb or less, more attention to schools, daycares, and afterschool facilities, better enforcement, and not replacing lead pipes with PVC or other dangerous pipes.
Read More »The Evidence Behind Clinical and Self-Breast Exams
We review the conflicting advice from healthcare professionals on performing self-breast exams so that you and your doctor can make the best decision for you.
Read More »NCHR Provides Recommendations for the Public Meeting Agenda to Reduce Added Sugar Consumption in the United States
January 22, 2024: NCHR recommends that FDA policies are discussed as a key strategy to reduce added sugar consumption at the national public meeting on hunger. The FDA should require targets for added sugar amounts in packaged food, hold restaurants accountable for disclosing added sugar content, and regulate food with artificial sweeteners.
Read More »NCHR Comments on USPSTF Draft Recommendations on Interventions for Adolescents with a High Body Mass Index
January 16, 2024: NCHR strongly supports USPSTF’s draft recommendation on using behavioral interventions to manage unhealthy weight gain in adolescents over six years of age with a body mass index at the 95th percentile for their age and sex. More research is needed to clearly show the safety and efficacy of weight loss medications in this patient population.
Read More »